Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (4)

2024

  1. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction

    Biochemical Pharmacology, Vol. 230

2023

  1. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

  2. Vessel-on-a-Chip: A Powerful Tool for Investigating Endothelial COVID-19 Fingerprints

    Cells, Vol. 12, Núm. 9

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13